Literature DB >> 8353231

Emergence of resistance to imipenem in Enterobacter isolates masquerading as Klebsiella pneumoniae during therapy with imipenem/cilastatin.

A F Ehrhardt1, C C Sanders, K S Thomson, C Watanakunakorn, I Trujillano-Martin.   

Abstract

Clinical isolates identified as Klebsiella pneumoniae by the Vitek, Enterotube II, and API 20E systems were recovered from a patient undergoing therapy with imipenem/cilastatin. These isolates were resistant to multiple beta-lactam agents, and some were even resistant to imipenem. Analysis revealed a Bush group 1 beta-lactamase, and imipenem resistance corresponded to the loss of outer-membrane proteins in strains expressing high levels of this beta-lactamase. Further characterization efforts yielded abnormal but positive results of tests for ornithine decarboxylase production and motility, and chromosomal homology to an Enterobacter cloacae ampR, ampC probe was detected. These results suggested that the organisms were actually of an Enterobacter species, perhaps Enterobacter aerogenes. Cefoxitin resistance may be a useful marker for preventing this misidentification in the future; misidentification of such organisms poses a hazard, as it may lead to inappropriate beta-lactam therapy for infections caused by organisms that have the potential for resistance due to inducible group 1 cephalosporinases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353231     DOI: 10.1093/clinids/17.1.120

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Study of an outbreak of cefoxitin-resistant Klebsiella pneumoniae in a general hospital.

Authors:  M Gazouli; M E Kaufmann; E Tzelepi; H Dimopoulou; O Paniara; L S Tzouvelekis
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 2.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Carbapenem resistance in a clinical isolate of Citrobacter freundii.

Authors:  J L Mainardi; P Mugnier; A Coutrot; A Buu-Hoï; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance.

Authors:  Y De Gheldre; N Maes; F Rost; R De Ryck; P Clevenbergh; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of OmpF and OmpC porin analogs.

Authors:  Hesna Yigit; Gregory J Anderson; James W Biddle; Christine D Steward; J Kamile Rasheed; Lourdes L Valera; John E McGowan; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Authors:  H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

7.  Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.

Authors:  P A Bradford; C Urban; N Mariano; S J Projan; J J Rahal; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  Imipenem resistance of enterobacter aerogenes mediated by outer membrane permeability.

Authors:  C Bornet; A Davin-Regli; C Bosi; J M Pages; C Bollet
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

9.  Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6.

Authors:  T Naas; L Vandel; W Sougakoff; D M Livermore; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Authors:  C C Sanders; E S Moland
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.